Form D · Biotechnology
Absco Therapeutics, Inc.
Allston, MA · CIK 0002023557
Offering snapshot reported Aug 27, 2025 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Aug 18, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 27, 2025 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| May 28, 2024 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-556003
Source: Form D, filed Aug 27, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephen Linderman | Director, Executive |
| Avik Som | Director |
| Carlo Giovanni Traverso | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
127 Western Avenue
Allston, MA, 02134
Allston, MA, 02134